NuMedii Names Industry Veteran Heather Arnett, Ph.D. as Vice President of Research
SAN MATEO, Calif., Nov. 1, 2018
SAN MATEO, Calif., Nov. 1, 2018 /PRNewswire/ -- NuMedii, Inc., today announced the appointment of Heather Arnett, Ph.D., as Vice President, Research. Heather is leading research discovery and early development at NuMedii based on the company's Artificial Intelligence Drug Discovery (AIDD) technology, which enables the discovery of novel targets and precision drug candidates across a number of therapeutic areas including inflammation, oncology and rare diseases like idiopathic pulmonary fibrosis (IPF).
"We are thrilled to have Heather join NuMedii in this vital role at this important time as we advance our development program to successfully translate AI hits into novel therapeutics. With her breadth of expertise in the discovery and development of large and small molecules, particularly in inflammation, fibrosis and immuno-oncology, Heather will play a critical role in helping us fulfill our mission of developing new therapies for patients with unmet medical needs, such as those with IPF, a fatal lung disease," said Gini Deshpande, Ph.D., chief executive officer, NuMedii.
Heather has more than 15 years' experience in large and small molecule drug discovery and development, and more than 30 publications in top-tier journals with research focused on diverse pathways in immunology, neuroscience and fibrotic diseases. Prior to joining NuMedii, she was Director of Research at Amgen where she spearheaded multiple immune modulatory therapy programs. While at Amgen, she built and managed a robust team of scientists and associates focused on filling the pipeline with new therapies for fibrotic and inflammatory diseases and immuno-oncology. A holder of multiple patents, Heather holds a Ph.D. in Neuroscience from the University of North Carolina at Chapel Hill and completed a National Multiple Sclerosis Society postdoctoral fellowship at Harvard Medical School and the Dana-Farber Cancer Institute.
"The opportunity to join NuMedii greatly appealed to me and I am honored to be here. I am excited to partner with Gini and our talented team to develop novel targets and precision drug candidates for diseases in need of effective treatment options. We look forward to collaborating with academic thought leaders, clinicians and patient communities in the development of these therapies and hope to make a real difference in the lives of individuals impacted by intractable diseases," said Dr. Arnett.
NuMedii's AIDD technology employs deep learnings of human biology consisting of hundreds of millions of structured molecular, pharmacological and clinical data points that the company has curated and harmonized. The company couples these data with proprietary machine learning and network-based algorithms to discover and advance precise, effective new drug candidates, as well as biomarkers predictive of efficacy for subsets of patients, in a broad spectrum of therapeutic areas including inflammation, cancer and orphan diseases.
About NuMedii, Inc.
NuMedii, Inc., has been pioneering the use of Big Data, Artificial Intelligence (AI) and systems biology since 2010 to accelerate the discovery of precision therapies to address high unmet medical needs. As a next generation biopharma company, NuMedii has built a powerful technology, AIDD (Artificial Intelligence for Drug Discovery), originally developed at Stanford University, that harnesses Big Data and AI to rapidly discover connections between drugs and diseases at a systems level. NuMedii has active R&D collaborations with several global pharmaceutical and biotech companies and patient-centric organizations to create pipeline and new products in multiple therapeutic areas including inflammation, oncology and rare diseases. For more information, please visit www.numedii.com.
SOURCE NuMedii, Inc.